Robert Rifkin, MD from Rocky Mountain Cancer Center discusses Carflizomib is extraordinarily active in myeloma and mainstay drug for physicians and patients at the 2017 American Society of Hematology.
Carflizomib is Extraordinarily Active in Myeloma Mainstay drug for physicians and patients
